CME: The Changing Landscape of NSCLC: MET Inhibitors

The Changing Landscape of NSCLC: MET Inhibitors

The Changing Landscape of NSCLC: MET Inhibitors

Find out about dysregulation of the MET pathway in NSCLC and the therapeutic potential of small molecule MET kinase inhibitors.

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Approximately 3 to 4 percent of the non-small cell lung cancer patient population as a whole harbors MET exon 14 skipping mutations that result in increased MET kinase protein levels and a constitutively active pathway. There is increasing excitement that these mutations, as well as MET gene amplification, can be specifically targeted with MET-directed approaches. Join us as Drs. Everett Vokes and Ross Camidge discuss both the dysregulation of the MET pathway in non-small cell lung cancer and the therapeutic potential of small molecule MET kinase inhibitors.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Everett E. Vokes, MD
    Chairman, Professor of Medicine
    The University of Chicago Medicine
    Chicago, IL

    Consulting Fees: AbbVie, Amgen, AstraZeneca, BMS, Celgene, Eli Lilly,
    EMD Serono, Genentech, GlaxoSmithKline, Merck, Novartis, Regeneron
    Dr. Vokes has disclosed his spouse receives honorarium from Ascendis Pharma, Radius Health and Takeda. 

    D. Ross Camidge, MD, PhD
    Director, Thoracic Oncology
    University of Colorado
    Aurora, CO

    Consulting Fees: AbbVie, EMD Serono

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Barry A. Feidel, PhD has nothing to disclose.
    • Jessica McGrory has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify the pathobiology of MET kinase pathway as a driver of tumorigenesis and metastasis and as a cause of resistance to therapy in NSCLC
    • Differentiate between the mechanisms of action leading to c-MET inhibition in various approved and investigational agents
    • Describe clinical evidence of the value of c-MET inhibitors as monotherapy or in combination with other agents in improving outcomes among distinct subsets of patients with NSCLC, including patients with brain metastases and/or EGFR-TKI resistance
  • Target Audience

    This activity is designed to meet the educational needs of oncologists, pathologists, and other healthcare professionals that manage patients with NSCLC.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    AGILE - Academy for Interprofessional Learning and Education - designs, develops, and delivers education across a broad spectrum of diseases and clinical conditions. Our mission is to serve as a trusted source of clinical information that helps healthcare professionals improve competence, performance, and patient outcomes

  • Commercial Support

    This activity is supported by an independent educational grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Agile. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Agile you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

    Disclaimer: Some products discussed in this activity may not have received regulatory approval by the US FDA for the treatment of patients. The FDA has stated that “good medical practice and the best interests of the patient require that physicians use legally available drugs, biologics and devices according to their best knowledge and judgement.” 

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.



We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free